Myriagon

MYRIAGON is developing a new class of medication to improve the quality of life for patients suffering from chemotherapy-induced neuropathic pain—a serious and often dose-limiting side effect of cancer treatment. This condition represents a major unmet medical need, as current therapies are often ineffective and cause unwanted side effects like sedation, tolerance, or dependence. 

Their novel compounds act via a completely new mechanism and have shown strong pain-suppressing effects in preclinical models, without affecting the central nervous system. With this promising approach, MYRIAGON aims to bring a safer and more effective treatment to patients who currently have few options.